Top

Published in:

Open Access 01-12-2019 | Migraine | Research article

Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study

Authors: William B. Young, J. Ivan Lopez, John F. Rothrock, Amelia Orejudos, Aubrey Manack Adams, Richard B. Lipton, Andrew M. Blumenfeld

Published in: The Journal of Headache and Pain | Issue 1/2019

Abstract

Background

OnabotulinumtoxinA is effective in treating chronic migraine (CM), but there are limited data assessing how allodynia affects preventive treatment responses. This subanalysis of the 108-week, multicenter, open-label COMPEL Study assessed the efficacy and safety of onabotulinumtoxinA in people with CM with and without allodynia.

Methods

Patients (n = 715) were treated with onabotulinumtoxinA 155 U every 12 weeks for 9 treatment cycles. The Allodynia Symptom Checklist was used to identify patients with allodynia (scores ≥3). The primary outcome for this subanalysis was reduction in monthly headache days from baseline for weeks 105 to 108 in groups with and without allodynia. Other outcomes included assessments of moderate to severe headache days, disability (using the Migraine Disability Assessment [MIDAS] questionnaire), and health-related quality of life (Migraine-Specific Quality-of-Life Questionnaire [MSQ] v2). Adverse events and their relation to treatment were recorded.

Results

OnabotulinumtoxinA was associated with a significant mean (SD) reduction in headache day frequency at week 108 relative to baseline in patients with (n = 289) and without (n = 426) allodynia (− 10.8 [7.1] and − 12.5 [7.4], respectively; both P < 0.001) that was significantly greater in patients without allodynia (P = 0.044 between-subgroup comparison). Moderate to severe headache days were significantly reduced at week 108 in patients with and without allodynia (− 9.6 [6.9] and − 10.5 [7.2]; both P < 0.001); reduction was similar between groups. MIDAS scores improved significantly at week 108 (− 53.0 [50.3] and − 37.7 [53.0]; both P < 0.001), with a significant between-group difference in favor of those with allodynia (P = 0.005). Similarly, MSQ subscale scores (Role Function Preventive, Role Function Restrictive, Emotional Function) significantly improved at week 108 for patients with and without allodynia: 20.6 (21.9) and 16.9 (20.7), 28.0 (23.3) and 24.7 (22.7), and 27.6 (26.5) and 24.9 (26.1), respectively (all P < 0.001). OnabotulinumtoxinA was well tolerated in patients with and without allodynia.

Conclusion

Results indicate that onabotulinumtoxinA is associated with reductions from baseline in multiple efficacy outcomes for up to 108 weeks whether or not allodynia is present. The allodynia group showed a smaller treatment response for reduction in headache days, but a similar or greater treatment response for improvement in other measures. No new safety concerns were identified.

Available only for authorised users

Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB (2010) Global prevalence of chronic migraine: a systematic review. Cephalalgia 30:599–609. https://doi.org/10.1111/j.1468-2982.2009.01941.x CrossRefPubMed

Headache Classification Committee of the International Headache Society (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38:1–211. https://doi.org/10.1177/0333102417738202 CrossRef

Benatto MT, Florencio LL, Carvalho GF, Dach F, Bigal ME, Chaves TC, Bevilaqua-Grossi D (2017) Cutaneous allodynia is more frequent in chronic migraine, and its presence and severity seems to be more associated with the duration of the disease. Arq Neuropsiquiatr 75:153–159. https://doi.org/10.1590/0004-282X20170015 CrossRefPubMed

Chen N, Zhang J, Wang P, Guo J, Zhou M, He L (2015) Functional alterations of pain processing pathway in migraine patients with cutaneous allodynia. Pain Med 16:1211–1220. https://doi.org/10.1111/pme.12690 CrossRefPubMed

Lipton RB, Munjal S, Buse DC, Bennett A, Fanning KM, Burstein R, Reed ML (2017) Allodynia is associated with initial and sustained response to acute migraine treatment: results from the American Migraine Prevalence and Prevention Study. Headache 57:1026–1040. https://doi.org/10.1111/head.13115 CrossRefPubMed

Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793–803. https://doi.org/10.1177/0333102410364676 CrossRefPubMed

Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804–814. https://doi.org/10.1177/0333102410364677 CrossRefPubMed

Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921–936. https://doi.org/10.1111/j.1526-4610.2010.01678.x CrossRefPubMed

Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC (2011) OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 51:1358–1373. https://doi.org/10.1111/j.1526-4610.2011.01990.x CrossRefPubMed

10.

Blumenfeld AM, Aurora SK, Laranjo K, Papapetropoulos S (2015) Unmet clinical needs in chronic migraine: rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine. BMC Neurol 15:100. https://doi.org/10.1186/s12883-015-0353-x CrossRefPubMedPubMedCentral

11.

Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A (2018) Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 19:13. https://doi.org/10.1186/s10194-018-0840-8 CrossRefPubMedPubMedCentral

12.

BOTOX® for injection, for intramuscular, intradetrusor, or intradermal use (onabotulinumtoxinA). Full Prescribing Information, Allergan plc, Irvine, CA, 2016

13.

Stewart W, Lipton R, Dowson A, Sawyer J (2001) Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology 56:S20–S28. https://doi.org/10.1212/WNL.56.suppl_1.S20 CrossRefPubMed

14.

Martin BC, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, Jhingran P (2000) Validity and reliability of the migraine-specific quality of life questionnaire (MSQ version 2.1). Headache 40:204–215. https://doi.org/10.1046/j.1526-4610.2000.00030.x CrossRefPubMed

15.

Bigal ME, Ashina S, Burstein R, Reed ML, Buse D, Serrano D, Lipton RB, AMPP Group (2008) Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology 70:1525–1533. https://doi.org/10.1212/01.wnl.0000310645.31020.b1 CrossRef

16.

Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, Serrano D, Stewart WF, American Migraine Prevalence Prevention Advisory Group (2008) Cutaneous allodynia in the migraine population. Ann Neurol 63:148–158. https://doi.org/10.1002/ana.21211 CrossRef

17.

Burstein R, Jakubowski M, Garcia-Nicas E, Kainz V, Bajwa Z, Hargreaves R, Becerra L, Borsook D (2010) Thalamic sensitization transforms localized pain into widespread allodynia. Ann Neurol 68:81–91. https://doi.org/10.1002/ana.21994 CrossRefPubMedPubMedCentral

18.

Burstein R, Jakubowski M, Rauch SD (2011) The science of migraine. J Vestib Res 21:305–314. https://doi.org/10.3233/VES-2012-0433 CrossRefPubMedPubMedCentral

19.

Burstein R, Collins B, Jakubowski M (2004) Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 55:19–26. https://doi.org/10.1002/ana.10786 CrossRefPubMed

20.

Orr SL, Friedman BW, Christie S, Minen MT, Bamford C, Kelley NE, Tepper D (2016) Management of adults with acute migraine in the emergency department: the American Headache Society evidence assessment of parenteral pharmacotherapies. Headache 56:911–940CrossRef

21.

Silberstein S, Lipton R, Dodick D, Freitag F, Mathew N, Brandes J, Bigal M, Ascher S, Morein J, Wright P, Greenberg S, Hulihan J (2009) Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 49:1153–1162. https://doi.org/10.1111/j.1526-4610.2009.01508.x CrossRefPubMed

22.

Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, Wang SJ (2008) Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 28:484–495. https://doi.org/10.1111/j.1468-2982.2008.01555.x CrossRefPubMed

23.

Dodick DW, Turkel CC, DeGryse RE, Diener HC, Lipton RB, Aurora SK, Nolan ME, Silberstein SD (2015) Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example. J Pain 16:164–175. https://doi.org/10.1016/j.jpain.2014.11.004 CrossRefPubMed

24.

Cole JC, Lin P, Rupnow MF (2009) Minimal important differences in the migraine-specific quality of life questionnaire (MSQ) version. Cephalalgia 29:1180–1187. https://doi.org/10.1111/j.1468-2982.2009.01852.x CrossRefPubMed

25.

Lipton RB, Munjal S, Buse DC, Fanning KM, Bennett A, Reed ML (2016) Predicting inadequate response to acute migraine medication: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 56:1635–1648. https://doi.org/10.1111/head.12941 CrossRefPubMed

26.

Serrano D, Lipton RB, Scher AI, Reed ML, Stewart WBF, Adams AM, Buse DC (2017) Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain 18:101. https://doi.org/10.1186/s10194-017-0787-1 CrossRefPubMedPubMedCentral

27.

Rendas-Baum R, Yang M, Varon SF, Bloudek LM, DeGryse RE, Kosinski M (2014) Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine. Health Qual Life Outcomes 12:117. https://doi.org/10.1186/s12955-014-0117-0 CrossRefPubMedPubMedCentral

28.

Rendas-Baum R, Bloudek LM, Maglinte GA, Varon SF (2013) The psychometric properties of the migraine-specific quality of life questionnaire version 2.1 (MSQ) in chronic migraine patients. Qual Life Res 22:1123–1133. https://doi.org/10.1007/s11136-012-0230-7 CrossRefPubMed

Title: Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study
Authors: William B. Young
J. Ivan Lopez
John F. Rothrock
Amelia Orejudos
Aubrey Manack Adams
Richard B. Lipton
Andrew M. Blumenfeld
Publication date: 01-12-2019
Publisher: Springer Milan
Keywords: Migraine
Headache
Published in: The Journal of Headache and Pain / Issue 1/2019
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-018-0952-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Letter to the editor: European headache federation guidelines on the use of monoclonal antibodies acting on the calcitonin gene-related peptide or its receptor for migraine prevention

Aura and Head pain: relationship and gaps in the translational models

Predicting treatment response using pharmacy register in migraine

Trigeminal autonomic cephalalgias presenting in a multidisciplinary tertiary orofacial pain clinic

Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care

CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?